Search

Displaying results 2341 - 2350 of 10000 in total
  1. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    the use of baricitinib for the treatment of COVID-19 in May 2022. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.

  2. Drug

    Prochlorperazine

    go.drugbank.com/drugs/DB00433
    ApprovedInvestigationalVet approved

    [label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors. … [L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956.

    Categories: Dopamine D2 Receptor Antagonists
  3. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration. … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue.

    Categories: Androgen Receptor Antagonists, Androgen Receptor Inhibitors
  4. Drug

    Ethoxzolamide

    go.drugbank.com/drugs/DB00311
    ApprovedWithdrawn

    It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. Its pharmacological activity thus confers the risk for hypokalemia.

  5. Drug

    Clobetasone

    go.drugbank.com/drugs/DB13158
    Approved

    Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis.

  6. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    to its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA. … [L48216] α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization of lymphocytes and thus contributing

    Categories: Integrin Receptor Antagonist
  7. Drug

    Erdosteine

    go.drugbank.com/drugs/DB05057
    ApprovedInvestigational

    Erdosteine has been shown to be safe and well tolerated in clinical trials. … Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier

  8. Drug

    Ethotoin

    go.drugbank.com/drugs/DB00754
    Approved

    The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. … The mechanism of action is probably very similar to that of phenytoin.

  9. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).

  10. Drug

    Aceclofenac

    go.drugbank.com/drugs/DB06736
    Approved

    In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug. … It displays high permeability to penetrate into synovial joints where in patients with osteoarthritis and related conditions, the loss of articular cartilage in the area causes joint pain, tenderness,